中国卫生标准管理
中國衛生標準管理
중국위생표준관리
CHINA HEALTH STANDARD MANAGEMENT
2015年
18期
129-130
,共2页
细菌性%下呼吸道感染%氨曲南%头孢噻肟
細菌性%下呼吸道感染%氨麯南%頭孢噻肟
세균성%하호흡도감염%안곡남%두포새우
Bacterial%Lower respiratory tract infections%Aztreonam%Cefotaxime
目的 研究分析使用氨曲南治疗细菌性下呼吸道感染患儿的临床效果.方法 根据我院2012~2013年接收的82例细菌性下呼吸道感染患儿进行研究,将其分成参照组和研究组,参照组使用头孢噻肟治疗,研究组使用氨曲南治疗,对两组的治疗效果进行比较分析.结果 研究组患者的痊愈率是65.85%,总有效率是92.68%,参照组痊愈率43.9%,总有效率75.61%,研究组的细菌清除率是92.31%,参照组90.74%,两组的对比存在统计学差异性,P<0.05,研究组共有3例不良反应病例,占7.32%,参照组有4例不良反应病例,占9.76%,两组患儿的不良反应几率相近,不存在统计学差异性,P>0.05.结论 氨曲南对细菌性下呼吸道感染患儿的治疗效果非常突出,临床中有效率高,安全可靠,是非常优秀的治疗方式.
目的 研究分析使用氨麯南治療細菌性下呼吸道感染患兒的臨床效果.方法 根據我院2012~2013年接收的82例細菌性下呼吸道感染患兒進行研究,將其分成參照組和研究組,參照組使用頭孢噻肟治療,研究組使用氨麯南治療,對兩組的治療效果進行比較分析.結果 研究組患者的痊愈率是65.85%,總有效率是92.68%,參照組痊愈率43.9%,總有效率75.61%,研究組的細菌清除率是92.31%,參照組90.74%,兩組的對比存在統計學差異性,P<0.05,研究組共有3例不良反應病例,佔7.32%,參照組有4例不良反應病例,佔9.76%,兩組患兒的不良反應幾率相近,不存在統計學差異性,P>0.05.結論 氨麯南對細菌性下呼吸道感染患兒的治療效果非常突齣,臨床中有效率高,安全可靠,是非常優秀的治療方式.
목적 연구분석사용안곡남치료세균성하호흡도감염환인적림상효과.방법 근거아원2012~2013년접수적82례세균성하호흡도감염환인진행연구,장기분성삼조조화연구조,삼조조사용두포새우치료,연구조사용안곡남치료,대량조적치료효과진행비교분석.결과 연구조환자적전유솔시65.85%,총유효솔시92.68%,삼조조전유솔43.9%,총유효솔75.61%,연구조적세균청제솔시92.31%,삼조조90.74%,량조적대비존재통계학차이성,P<0.05,연구조공유3례불량반응병례,점7.32%,삼조조유4례불량반응병례,점9.76%,량조환인적불량반응궤솔상근,불존재통계학차이성,P>0.05.결론 안곡남대세균성하호흡도감염환인적치료효과비상돌출,림상중유효솔고,안전가고,시비상우수적치료방식.
Objective To study the clinical Results of aztreonam for the treatment of lower respiratory tract infections in children.Methods Received 82 cases of lower respiratory tract infection in children from 2012 to 2013. Randomly divided into reference and study groups,Referring to the use of cefotaxime treatment group, the study group using aztreonam therapy, the treatment effect of the two groups were compared.Results The study group of patients cure rate is 65.85%, the total efficiency is 92.68%, the reference group of patients cure rate is 43.9%, the total efficiency of 75.61%, the study group of bacterial clearance rate was 92.31%,90.74% of reference group, There were significant differences,P<0.05,Study group consisted of three cases of adverse reactions cases, accounting for 7.32%, the reference group had 4 cases of adverse reactions cases, accounting for 9.76%, the probability of adverse reactions is similar between two groups, there is no significant difference,P>0.05. Conclusion Aztreonam for treatment of bacterial lower respiratory tract infection in children is very prominent, clinical high efficiency, safety and reliability, is a very good treatment.
